Indeed, the vasculatures and the sizes of our bladder cancer models are not responsive to the soluble VEGFR-3 treatment, which might be due to the low expression of VEGFR-3 in the tumor vasculatures. This evidence concerns the gene FLT4 and urinary bladder cancer.